Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-131 Nivolumab for Richter's transformation
jRCT2071250005Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in Richter's syndrome (RS), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and 1 more, sponsored by Ono Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2071250005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250005.